Navigation Links
Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
Date:12/5/2007

WESTMINSTER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will participate on the "Better Drugs & Novel Approaches To Cancer Therapy" panel at the 2007 RBC Capital Markets Healthcare Conference in New York.

The panel presentation will take place at 1:30 p.m. (Eastern) on December 13, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through December 28, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at present:, ... influenza shot seems to be having no effect on keeping this particularly bad strain of ... people around are coughing, sneezing, or sniffling , These facts are well-known ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. Mehryar ... official journal of The American Society for Aesthetic Plastic Surgery, in which he ... designed to correct drooping, retracted lower eyelids, which usually result from genetics, injury, ...
(Date:1/16/2017)... ... , ... One thing common to all types of cancer is that it’s ... The money spent screening for and treating cancer in the United States is estimated ... more than in any other country that has an advanced healthcare system, sometimes spending ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... New York, NY (PRWEB) , ... January 15, 2017 , ... ... growing strategic accounts in the United States for the asthma & allergy friendly mark. ... of America to independently test and identify consumer products to be more suitable for ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... -- The global pacemaker market is expected to reach ... report by Grand View Research, Inc. The heightening prevalence ... coverage is a key driving factor governing the growth ... devices are supporting the expansion of this vertical. ... growth rendering driver for this market. A death estimate ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek H. ... Law Firm, was recently appointed Liaison Counsel in ... for all Xarelto cases. In this role, Potts was ... and will actively assist the Court and Co Lead ... Milstein Adelman Jackson Fairchild & Wade ...
(Date:1/16/2017)...  Harrington Discovery Institute at University Hospitals in ... of The Harrington Project for Discovery & Development ... in collaboration with Alzheimer,s Drug Discovery Foundation (ADDF), ... Harrington Discovery Institute collaborations are ... into new medicines that will improve human health, ...
Breaking Medicine Technology: